Genetics Generation Advancement (ROCO:4160) Cyclically Adjusted FCF per Share: NT$0.29 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4160 Genetics Generation Advancement Corp ROCO:4160
72 GF Score
Price NT$39.15
GF Value NT$51.32
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Genetics Generation Advancement Cyclically Adjusted FCF per Share?

Genetics Generation Advancement ROCO:4160 +0.64% 72 Cyclically Adjusted FCF per Share is NT$0.29 as of Jun. 2026. GuruFocus rates ROCO:4160 with a GF Score™ of 72/100 and a GF Value™ of NT$51.32 (Modestly Undervalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Genetics Generation Advancement's adjusted free cash flow per share for the three months ended in Jun. 2026 was NT$-0.571. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is NT$0.29 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Genetics Generation Advancement's average Cyclically Adjusted FCF Growth Rate was 20.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-09-12), Genetics Generation Advancement's current stock price is NT$39.15. Genetics Generation Advancement's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was NT$0.29. Genetics Generation Advancement's Cyclically Adjusted Price-to-FCF of today is 135.00.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Genetics Generation Advancement was 2720.62. The lowest was 91.21. And the median was 182.09.


Genetics Generation Advancement  (ROCO:4160) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Genetics Generation Advancement's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=39.15/0.29
=135.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Genetics Generation Advancement was 2720.62. The lowest was 91.21. And the median was 182.09.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Genetics Generation Advancement Cyclically Adjusted FCF per Share Related Terms


Genetics Generation Advancement Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Genetics Generation Advancement's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetics Generation Advancement Cyclically Adjusted FCF per Share Chart

Genetics Generation Advancement Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.72 -0.39 0.27 0.36 0.30

Genetics Generation Advancement Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.37 0.30 0.41 0.29

ROCO:4160 vs TMO, DHR, NTRA: Cyclically Adjusted FCF per Share Comparison

For the Diagnostics & Research subindustry, Genetics Generation Advancement's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetics Generation Advancement Cyclically Adjusted Price-to-FCF vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Genetics Generation Advancement's Cyclically Adjusted Price-to-FCF falls into.


ROCO:4160
72GF Score
Genetics Generation Advancement Corp ROCO:4160
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genetics Generation Advancement Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genetics Generation Advancement's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.571/333.9520*333.9520
=-0.571

Current CPI (Jun. 2026) = 333.9520.

Genetics Generation Advancement Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.667 241.428 -0.923
201612 0.146 241.432 0.202
201703 -0.186 243.801 -0.255
201706 0.055 244.955 0.075
201709 -0.493 246.819 -0.667
201712 0.640 246.524 0.867
201803 -0.249 249.554 -0.333
201806 0.005 251.989 0.007
201809 -0.579 252.439 -0.766
201812 0.657 251.233 0.873
201903 0.040 254.202 0.053
201906 -0.021 256.143 -0.027
201909 -0.438 256.759 -0.570
201912 0.202 256.974 0.263
202003 0.444 258.115 0.574
202006 -0.854 257.797 -1.106
202009 0.350 260.280 0.449
202012 0.256 260.474 0.328
202103 -0.474 264.877 -0.598
202106 -0.029 271.696 -0.036
202109 0.784 274.310 0.954
202112 -0.369 278.802 -0.442
202203 0.276 287.504 0.321
202206 0.291 296.311 0.328
202209 0.895 296.808 1.007
202212 0.116 296.797 0.131
202303 0.638 301.836 0.706
202306 0.186 305.109 0.204
202309 -0.092 307.789 -0.100
202312 1.461 306.746 1.591
202403 0.489 312.332 0.523
202406 -0.379 314.175 -0.403
202409 0.947 315.301 1.003
202412 0.920 315.605 0.973
202503 -1.662 319.799 -1.736
202506 1.046 322.561 1.083
202509 -1.100 324.800 -1.131
202512 -0.252 324.054 -0.260
202603 0.337 330.213 0.341
202606 -0.571 333.952 -0.571

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of NT$0.29 mean?
Genetics Generation Advancement (ROCO:4160) has a Cyclically Adjusted FCF per Share of NT$0.29 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Genetics Generation Advancement and its competitors.
Is Genetics Generation Advancement's Cyclically Adjusted FCF per Share too high?
Genetics Generation Advancement's current Cyclically Adjusted FCF per Share is NT$0.29. Overall, Genetics Generation Advancement has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's Cyclically Adjusted FCF per Share compare to TMO and DHR?
Genetics Generation Advancement's Cyclically Adjusted FCF per Share of NT$0.29 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted FCF per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Genetics Generation Advancement and its competitors. Genetics Generation Advancement's current Cyclically Adjusted FCF per Share is NT$0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$51.32, compared to a current price of NT$39.15 — trading 23.7% below its estimated fair value. The current Cyclically Adjusted FCF per Share is NT$0.29. Genetics Generation Advancement's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current Cyclically Adjusted FCF per Share is NT$0.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?

Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued. The current stock price of NT$39.15 is trading 23.7% below its estimated GF Value™ of NT$51.32. GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.

Key valuation signals for ROCO:4160:

  • Cyclically Adjusted FCF per Share: NT$0.29
  • GF Value™: NT$51.32 vs. price of NT$39.15 (23.7% below fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genetics Generation Advancement Business Description

Address No. 28, Lane 36, Xinhu 1st Road, 6th Floor, Neihu District, Taipei, TWN, 11494
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
72GF Score

Get the complete analysis for ROCO:4160

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$39.15
Price
NT$51.32
GF Value